医药行业创新药周报：2024年9月第三周创新药周报

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry as of September 22, 2024 [1]. Core Insights - The report highlights that the A-share innovative drug sector increased by 4.28% in the third week of September, underperforming the CSI 300 index by 0.84 percentage points. The biopharmaceutical sector rose by 0.42% [12][13]. - In the Hong Kong market, the innovative drug sector rose by 2.38%, outperforming the Hang Seng Index by 2.81 percentage points [15]. - The XBI index in the US increased by 1.16%, with a cumulative increase of 9.1% over the past six months [17]. - The report notes that three new drugs were approved for market in China in September, with no new indications approved [18]. - In the US, one NDA and one BLA were approved in September, with one NDA approved in the third week of September [20]. Summary by Sections 1. Market Performance - A-share innovative drug sector: +4.28% this week, -3.33% over the last six months [12][13]. - Hong Kong innovative drug sector: +2.38% this week, +4.99% over the last six months [15]. - XBI index: +1.16% this week, +9.1% over the last six months [17]. 2. Drug Approvals - September saw three new drugs approved in China, with no new indications [18]. - In the US, one NDA and one BLA were approved in September, with one NDA approved in the third week [20]. 3. Key Drug Developments - The report details the progress of GLP-1RA drugs, with 11 approved globally for diabetes, and three in NDA stage [4]. - The report also mentions the sales performance of various GLP-1 drugs, highlighting significant revenue growth for certain products [10].